FBRX - BiomX: Undervalued With Multiple Upcoming Catalysts

• Utilizing its proprietary BOLT and synthetic biology platforms, BiomX develops natural and engineered phage therapeutic cocktails to treat chronic diseases ranging from acne, IBD, PSC, CF, A. Dermatitis and colorectal cancer.
• BiomX currently has four Phase 2 clinical trial readouts during the next 8 months including a Phase 2 acne trial readout late this month.
• It has entered into collaboration agreements with Boehringer Ingelheim, Janssen as well as a major international cosmetics company.  Lead investors include Orbimed, Takeda, and J&J.
• Trading at an all-time low, Israel-based BiomX has a market cap of only $85 million with cash of $47 million (June 30th), sufficient to operate until at least mid-2023.
• BiomX dropped 60% since March. It has become a "show me" story following recent microbiome therapeutic trial failures by Seres and Forte. While considered high-risk, there is substantial upside if one or more of its Phase 2 trials are successful.

For further details see: